热门关键字:经济学家    部委学者

微信咨询

微信咨询

手机网站二维码

手机网站

热门

智库专家

专家动态

当前位置:网站首页 >> 智库专家 >> 查看详情
Prof. Limin Chen

Prof. Limin Chen

Dr.LiminChen,aprofessorwithChineseAcademyofMedicalSciences(CAMS)/PekingUnionMedicalCollege(PUMC)andalsoanaffiliatedscientistwiththeUniversityofToronto,nowisthedirectorandchiefscientificofficerofthecenterfortransfusiontransmittedinfectiousdiseases,InstituteofBloodTransfusion(IBT),CAMS/PUMC,MemberoftheAmericanAssociationforStudiesofLiverDiseases(AASLD)andCanadianAssociationforStudiesofLiver(CASL).HegothisMD,MScinbiochemistryandmolecularbiologyinChina,PhDinmoleculargeneticsattheUniversityofToronto.Dr.ChenobtainedhispostdoctoraltrainingbothattheMerckResearchLaboratoriesandattheHarvardMedicalSchool.CurrentlyDr.Chen’sresearchfocusesonthevirus-hostinteractionofthehepatitisviruses,especiallyHCVandHBV.HepioneeredtheworkonidentificationoftheresponsesignatureandproposedanovelmechanismonhowHCVexploitshostinnateimmuneresponsetobenefititspersistentinfectionandresistancetointerferon-basedtherapy.

http://www.zcmsonline.com/index.php/zkzj/98810.html

  • 联系方式:
  • 手机号码:
  • 联系邮箱:
  • 助理电话:

详细介绍

Dr. Limin Chen, a professor with Chinese Academy of Medical Sciences (CAMS)/Peking Union Medical College (PUMC) and also an affiliated scientist with the University of Toronto, now is the director and chief scientific officer of the center for transfusion transmitted infectious diseases, Institute of Blood Transfusion (IBT), CAMS/PUMC, Member of the American Association for Studies of Liver Diseases (AASLD) and Canadian Association for Studies of Liver (CASL). He got his MD, MSc in biochemistry and molecular biology in China, PhD in molecular genetics at the University of Toronto. Dr. Chen obtained his postdoctoral training both at the Merck Research Laboratories and at the Harvard Medical School . Currently Dr. Chen’s research focuses on the virus-host interaction of the hepatitis viruses, especially HCV and HBV. He pioneered the work on identification of the response signature and proposed a novel mechanism on how HCV exploits host innate immune response to benefit its persistent infection and resistance to interferon-based therapy.